Chemokines and chemokine receptors in renal transplantation--from bench to bedside.
Attraction of mononuclear cells to sites of inflammation requires a close interplay of the inflammatory signal presented via chemokines and specific receptors on effector cells. First studies on acute renal transplant rejection demonstrated the involvement of CC-chemokines, such as RANTES, MIP-1alpha, MIP-1beta and MCP-1, as well as CXC-chemokines such as IL-8 and IP-10, correlating with expression of the corresponding chemokine receptors, CCR1, CCR5 and CCR2 as well as CXCR3. Since then, the pathophysiologic relevance has been extended to chronic allograft nephropathy and transplant glomerulopathy. Chemokine expression can be triggered by different stimuli, e.g. brain death, ischemia, HLA-mismatch and infection. Furthermore, anti-inflammatory chemokines have been identified. Chemokine receptor 7, e.g. enhances homing of lymphocytes to lymphatic tissues and the Duffy antigen receptor, DARC, a non-specific receptor that binds and inactivates different chemokines. While measurement of chemokine expression in clinical transplantation may facilitate the differential diagnosis of allograft dysfunction, knowledge of the chemokine network has also widened the understanding of transplant rejection and opened novel therapeutic approaches. Observations from humans with mutations of the chemokine network as well as transplantation of animals with targeted deletions in this system suggest that manipulations of chemokine signalling may improve the success rates of transplantation. Blocking chemokines unselectively with Met-RANTES or specifically with small molecule inhibitors of various chemokine receptors has lead to improved outcome in animal models. Currently, first human trials are under way to investigate drugs that stimulate lymphocyte homing. Inhibitors of CCR1 and CCR5 are being tested for other human diseases and may eventually be available in transplantation. Nonetheless, chemokine blockade my rather serve as an adjunct in the management of transplant recipients than a new "magic bullet".
Fischereder
M
M
Medizinische Poliklinik Innenstadt, Klinikum der Ludwig-Maximilians Universität München, Pettenkoferstr. 8a, 80336 München, Germany. Michael.Fischereder@med.uni-muenchen.de
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000818:Animals; D065100:CCR5 Receptor Antagonists; D018925:Chemokines / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000502:physiology*; D002633:Chemotaxis / Q000187:drug effects / Q000502:physiology; D002986:Clinical Trials as Topic; D004375:Duffy Blood-Group System; D000068876:Fingolimod Hydrochloride; D006084:Graft Rejection / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology; D006801:Humans; D016030:Kidney Transplantation / Q000502:physiology*; D023421:Models, Animal; D011409:Propylene Glycols / Q000627:therapeutic use; D054389:Receptors, CCR1; D011956:Receptors, Cell Surface / Q000172:deficiency; D019707:Receptors, Chemokine / Q000037:antagonists & inhibitors / Q000502:physiology*; D020123:Sirolimus / Q000627:therapeutic use; D013110:Sphingosine / Q000031:analogs & derivatives / Q000627:therapeutic use
C473745:ACKR1 protein, human; D000806:Angiotensin-Converting Enzyme Inhibitors; C515300:CCR1 protein, human; D065100:CCR5 Receptor Antagonists; D018925:Chemokines; D004375:Duffy Blood-Group System; D011409:Propylene Glycols; D054389:Receptors, CCR1; D011956:Receptors, Cell Surface; D019707:Receptors, Chemokine; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine; D020123:Sirolimus